Integra Lifesciences Holdings Corp
$1.76B- Market cap
- $1.30B
- Debt
- +$726.56M
- Cash
- −$263.74M
Capital structure 64% equity / 36% debt · EV / Revenue 1.08x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: IART stock price at premium vs ZUMZ $16.72 current versus $6.88 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZUMZ's multiple
Implied fair value · at IART's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: IART FY 2025 (ended Dec 31, 2025) · ZUMZ FY 2026 (ended Jan 31, 2026). Fiscal years are not aligned.
Trendline
11 fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 64% equity / 36% debt · EV / Revenue 1.08x
Capital structure 60% equity / 40% debt · EV / Revenue 0.41x · EV / EBITDA 8.34x
IART carries the larger enterprise value at $1.76B against $378.16M; ZUMZ trades on the lower EV / Revenue multiple (0.41x vs 1.08x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
INTEGRA LIFESCIENCES HOLDINGS CORP · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
ZUMIEZ INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.70x
0.62x
Net debt / EBITDA
Leverage against operating earnings
-0.92x
1.63x
Cash and equivalents
Liquid reserves on the balance sheet
$263.74M
$127.86M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ZIMMER BIOMET HOLDINGS, INC.
IART vs ZBH
STRYKER CORP
IART vs SYK
BECTON DICKINSON & CO
IART vs BDX
Edwards Lifesciences Corp
IART vs EW
BAXTER INTERNATIONAL INC
IART vs BAX
TELEFLEX INC
IART vs TFX
ABERCROMBIE & FITCH CO /DE/
IART vs ANF
AMERICAN EAGLE OUTFITTERS INC
IART vs AEO
Boot Barn Holdings, Inc.
IART vs BOOT
Victoria's Secret & Co.
IART vs VSCO
$726.56M
$201.82M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.